MARK2 and cancer: KEGG pathway analysis revealed significant results (P < 0.05; FDR < 0.05) for three pathways: the phosphoinositide 3-kinase-serine/threonine kinase (PI3K-AKT) signaling pathway (involving CD19, BRCA1, PDGFA, CDKN1A, and TLR4), bladder cancer (involving CDKN1A and MMP1), and microRNAs in cancer (involving CDKN1A, PDGFA, and BRCA1; (Fig 3, Table 4)